[14C]cadralazine: absorption, distribution and excretion in rat and dog
- 7 Downloads
Absorption, distribution and excretion of [14C]cadralazine in rat after oral and i.v. administration of 3 mg/kg were studied. Plasma levels after oral administration of 10 and 45 mg/kg were also evaluated. A direct relation between dose and plasma levels was demonstrated. The drug was well absorbed, disappeared very rapidly from plasma, and was distributed in all the organs examined, with the highest concentration in liver, kidney, and gastrointestinal tract. For more than 4 days excretion was essentially through the urine (75.6% after i.v. and 80% after oral administration), whereas faecal and biliary excretions were quite low. The total recovery was respectively 77.6% and 83.2% after i.v. and oral administration of 3 mg/kg, with the greatest amount (65–70% of the administered dose) appearing in the first 4 to 7 hours. Placental transfer and excretion of radioactivity with milk were demonstrated. Drug-protein binding was 25.9%. Elimination of14CO2 was not observed. Plasma levels in dog, after oral and i.v. administration of 1 mg/kg of labelled compound, showed similar behaviour to that observed in the rat. Binding of the radioactivity to erythrocytes was found; the radioactivity values observed up to 24 hours were constant with time and not dependent on the decreasing plasma levels. The total recovery (urine and faeces) in the dog over 4 days was 71.1% and 82.1% after oral and i.v. dose, respectively. Preliminary metabolic approaches in rats showed that cadralazine was essentially excreted as unchanged drug in the presence of minor metabolites.
Key wordsAbsorption distribution excretion [14C]cadralazine rat dog
Unable to display preview. Download preview PDF.
- 1.Pifferi, G., Parravicini, F., Scarpitta, G., and Semeraro, C. (1978): 5th Int. Symp. Med. Chemistry, Brighton, September 4–7. Synthesis and antihypertensive activity of new 6-substituted 3-alkyl- and 3-acyl-hydrazinopyridazines.Google Scholar
- 2.Parravicini, F., Scarpitta, G., Dorigotti, L., and Pifferi, G. (1979): Farmaco (Sci.), Derivati della 3-idrazinopiridazina. Nota III. Sintesi ed attivita antiipertensiva di nuove 3-(2-acilidrazino)-piridazine-6-alchilamino sostituite.34, 299–310.Google Scholar
- 3.Carpi, C., Dorigotti, L., and Semeraro, C. (1978): 7th Int. Congress of Pharmacology (IUPHAR), Paris, July 16–21. Pharmacological profile of a new antihypertensive drug: Ethyl-2-[6-[(2-hydroxypropyl)methylamino]-3-pyridazinyl]hydrazinecarboxylate (ISF 2469).Google Scholar
- 4.Simonotti, L., Zanol, M., Citerio, L., and Pifferi, G. (1980): 7th Int. Symp. on Mass Spectrometry in Biochemistry, Medicine and Environmental Research, Milan, June 16–18. Degradation and metabolic studies on cadralazine, a new antihypertensive agent.Google Scholar
- 5.Carpi, C., Dorigotti, L., and Semeraro, C. (1980): 3rd Joint Meeting of British and Italian Pharmacological Societies, Verona, June 30-July 1. Cadralazine and its identified metabolites: Comparative effects on blood pressure and on arterial smooth muscle.Google Scholar
- 7.Van Brummelen, P., Bühler, F.R., Kiowski, W., Bolli, P., and Bertel, O. (1979): Int. J. Clin. Pharmacol. Biopharmacol., Antihypertensive efficacy of a new long-acting vasodilator, ISF 2469, in combination with a beta-blocker and a diuretic.17, 380–385.Google Scholar
- 8.Amann, F.W., and Bühler, F.R. (1979): Clin. Eur., Long-term antihypertensive therapy with a new vasodilator, ISF 2469, in combination with a beta-blocker and a diuretic.18, 1028–1034.Google Scholar